Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

View:
Post by kuatolives on Oct 31, 2016 9:10pm

Monday Math ..

If Yosprala can make 25 million in 2017, that'll put revenues around:

25 million: Yosprala (Just pulling this number out my backside)
90 million: Toprol
50 million: Rest of business (with almost no growth)
----------
165M give or take.

If Aralez can achieve the industry average of 2.8x price to sales, this would put the market cap around 462M, or a 78% increase from today's level which would put ARLZ around $7.25.
Comment by goldbug83 on Nov 01, 2016 3:13am
I hope sales are in the $50+mil range and strong quarterly growth numbers for 2017. But they need to be able to turn a profit too. PHM has stagnate revenues of ~133M but can't turn a profit and look how they are valued. (I am not comparing ARZ to PHM by any means just using as a comparison of Revenues to Profits.) The shorts are currently making a killing which should bottom out in the next ...more